Janelle D'Alvise - 22 Jun 2022 Form 4 Insider Report for Acasti Pharma Inc. (GRCE)

Role
PRESIDENT & CEO, Director
Signature
/s/ Jason Comerford, attorney-in fact for Ms. D'Alvise
Issuer symbol
GRCE
Transactions as of
22 Jun 2022
Net transactions value
$0
Form type
4
Filing time
23 Jun 2022, 16:33:34 UTC
Previous filing
16 Nov 2021
SEC
View on sec.gov

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Underlying Class Amount Exercise Price Ownership Footnotes
transaction ACST Stock Options (Right to Buy) Award $0 +560,000 $0.000000 560,000 22 Jun 2022 Class A Common Shares 560,000 $0.8900 Direct F1, F2
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id Content
F1 Based on conversion of exercise price of C$1.15 into U.S. dollars based on an exchange rate of C$1.00 = US$0.7727 on the date of grant.
F2 Stock options granted on 06/22/2022 under Acasti Pharma Inc.'s Stock Option Plan and become exercisable evenly and on a quarterly basis over 36 months.